Eucalyptus Safety

CD19 CAR T appears to have a more favorable safety profile in SLE than in B-cell lymphoma. TPS does not appear to induce seizure activity, unlike repeated transcranial magnetic stimulation. Eucalyptus has been thoroughly studied and is considered very safe. Eucalyptus has well-established efficacy across respiratory, antimicrobial, and anti-inflammatory applications. Reported adverse effects are mild to moderate, transient, and occur in both active and placebo conditions. CRS events in autoimmune disease CAR T cohorts have mostly been grade 1–2. Animal studies found no brain damage at energy levels far above those permitted in humans. No serious adverse effects have been reported in healthy participants or clinical populations. SLE patients have elevated baseline cardiovascular risk that must be included in pretreatment risk-benefit assessment. Secondary malignancy attribution is complicated because autoimmune disease patients already have elevated lymphoma risk. ICANS appears rare in published autoimmune disease CAR T series.